Digoxin in heart failure and cardiac arrhythmias

Medical Journal of Australia

Volumn 179, Issue 2, 2003, Pages 98-102

  Campbell, Terence J ^a   MacDonald, Peter S ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; CARVEDILOL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYPERICUM PERFORATUM EXTRACT; OLEANDER EXTRACT; PLACEBO; PLANT EXTRACT; POTASSIUM SPARING DIURETIC AGENT; QUINIDINE; SENNA EXTRACT; SPIRONOLACTONE; SQUILL; STROPHANTUS EXTRACT; UNCLASSIFIED DRUG; VERAPAMIL;

BRADYCARDIA; CARDIOMEGALY; CARDIOTOXICITY; CHRONIC DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DIASTOLE; DIGITALIS INTOXICATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FATALITY; DRUG TOXICITY; ELDERLY CARE; EXERCISE; GYNECOMASTIA; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART DEATH; HEART FAILURE; HEART SOUND; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HERB; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; LIFESTYLE; LOW DRUG DOSE; MORTALITY; NAUSEA; OLEANDER; OPTIMAL DRUG DOSE; PRIMARY HEALTH CARE; QUALITY OF LIFE; RANDOMIZATION; REVIEW; SINUS RHYTHM; SITTING; STROPHANTHUS; SYMPTOMATOLOGY; TREATMENT INDICATION; VISUAL DISORDER; VOMITING;

EID: 0041528342     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2003.tb05445.x     Document Type: Review

References (26)

1. Withering W. An account of the foxglove and some of its medical uses, with practical remarks on dropsy and other diseases. In: Willus FA, Keys TE, editors. Classics of Cardiology: A Collection of Classic Works on the Heart and Circulation with Comprehensive Biographic Accounts of the Authors. Malabar, Fla: Krieger, 1983.
2. Braunwald E. Heart failure. In: Thorn GW, Adams R, Braunwald E, et al, editors. Harrison's Principles of Internal Medicine. New York: McGraw-Hill, 1977: 1178-1186.
3. Ryan TJ, Bailey KR, McCade CH, et al. The effects of digitalis on survival in high-risk patients with coronary artery disease. The Coronary Artery Surgery Study (CASS). Circulation 1983; 67: 735-742.
4. Bigger JT Jr, Fleiss JL, Rolnitzky LM, et al. Am J Cardiol 1985; 55: 623-630.
5. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-1475.
6. Meijler FL. An "account" of digitalis and atrial fibrillation. J Am Coll Cardiol 5 (5 Suppl A): 60A-68A.
7. Packer M. The development of positive inotropic agents for chronic heart failure: How have we gone astray? J Am Coll Cardiol 1993; 22 (4 Suppl A): 119A-126A.
8. Van Veldhuisen DJ, Man In 't Veld AJ, Dunselman PH, et al. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: Results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol 1993; 22: 1564-1573.
9. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533.
10. Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial. PROVED Investigate Group. J Am Coll Cardiol 1993; 22: 955-962.
11. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993; 329: 1-7.
12. Khand A, Rankin AC, Martin W, et al. Carvedilol or digoxin for the treatment of atrial fibrillation in heart failure patients? Eur Heart J 2000; 21 (Abstract Suppl): 123.
13. National Health and Medical Research Council. A Guide to the Development, Implementation and Evaluation of Clinical Practice Guidelines. Canberra: NHMRC, Auslnfo, 1999.
14. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347: 1403-1411.
15. Gheorghiade M, Hall VB, Jacobsen G, et al. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation 1995, 92: 1801-1807.
16. Eichhorn EJ, Gheorghiade M. Digoxin - New perspective on an old drug. N Engl J Med 2002; 347: 1394-1395.
17. Warren JL, McBean AM, Hass SL, et al. Hospitalizations with adverse events caused by digitalis therapy among elderly Medicare beneficiaries. Arch Intern Med 1994; 154: 1482-1487.
18. Masoudi FA, Havranek EP, Smith G, et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003; 41: 217-223.
19. Beasley R, Smith DA, McHaffie DJ. Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation. BMJ 1985; 290: 9-11.
20. Roth A, Harrison E, Mitani G, et al. Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986; 73: 316-324.
21. Wyse DG, Waldo AL, Domanski MJ, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
22. Olshansky B, Warner A, Solomon A, et al. Rate control in atrial fibrillation: A substudy of the AFFIRM trial [abstract]. Circulation 2002; 106 (Suppl II): II-633.
23. Falk RH, Knowlton AA, Bernard SA, et al. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. Ann Intern Med 1987; 106: 503-506.
24. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Intravenous digoxin in acute atrial fibrillation. Eur Heart J 1997; 18: 649-654.
25. Fuster V, Ryden LE. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001; 38: 1231-1265.
26. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: The effect of digoxin. Br Heart J 1990; 63: 225-227.